Literature DB >> 21357266

IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.

Nasim Akhtar Ansari1, Rajiv Kumar, Shalini Gautam, Susanne Nylén, Om Prakash Singh, Shyam Sundar, David Sacks.   

Abstract

IL-10 is believed to underlie many of the immunologic defects in human visceral leishmaniasis (VL). We have identified CD4(+)CD25(-)Foxp3(-) T cells as the major source of IL-10 in the VL spleen. IL-27, a member of the IL-6/IL-12 cytokine family, has been shown to promote development of IL-10-producing T cells, in part by upregulating their production of autocrine IL-21. We investigated whether IL-27 and IL-21 are associated with human VL. IL-27 was elevated in VL plasma, and at pretreatment, spleen cells showed significantly elevated mRNA levels of both IL-27 subunits, IL-27p28 and EBI-3, as well as IL-21, compared with posttreatment biopsies. CD14(+) spleen cells were the main source of IL-27 mRNA, whereas CD3(+) T cells were the main source of IL-21. IL-27 mRNA could be strongly upregulated in normal donor macrophages with IFN-γ and IL-1β, conditions consistent with those in the VL spleen. Last, a whole-blood assay revealed that most VL patients could produce Ag-specific IFN-γ and IL-10 and that the IL-10 could be augmented with recombinant human IL-21. Thus, proinflammatory cytokines acting on macrophages in the VL spleen have the potential to upregulate IL-27, which in turn can induce IL-21 to expand IL-10-producing T cells as a mechanism of feedback control.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357266      PMCID: PMC3076633          DOI: 10.4049/jimmunol.1003588

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

2.  EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappa B activation.

Authors:  Stefan Wirtz; Christoph Becker; Massimo C Fantini; Edward E Nieuwenhuis; Ingrid Tubbe; Peter R Galle; Hans-Jörg Schild; Mark Birkenbach; Richard S Blumberg; Markus F Neurath
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

3.  Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine.

Authors:  Rajiv Kumar; Yasuyuki Goto; Kamlesh Gidwani; Karen D Cowgill; Shyam Sundar; Steven G Reed
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

4.  Splenic cytokine responses in Indian kala-azar before and after treatment.

Authors:  R T Kenney; D L Sacks; A A Gam; H W Murray; S Sundar
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

5.  Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology.

Authors:  Lucia E Rosas; Anjali A Satoskar; Kimberly M Roth; Tracy L Keiser; Joseph Barbi; Christopher Hunter; Frederic J de Sauvage; Abhay R Satoskar
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

6.  Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis.

Authors:  E M Carvalho; O Bacellar; C Brownell; T Regis; R L Coffman; S G Reed
Journal:  J Immunol       Date:  1994-06-15       Impact factor: 5.422

7.  Genome-wide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappaB binding sites in the human EBI3 promotor.

Authors:  Marco A Poleganov; Malte Bachmann; Josef Pfeilschifter; Heiko Mühl
Journal:  Mol Immunol       Date:  2008-03-11       Impact factor: 4.407

8.  Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells.

Authors:  Simona Stäger; Asher Maroof; Soombul Zubairi; Stephanie L Sanos; Manfred Kopf; Paul M Kaye
Journal:  Eur J Immunol       Date:  2006-07       Impact factor: 5.532

9.  Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose.

Authors:  Margarida Saraiva; Jillian R Christensen; Marc Veldhoen; Theresa L Murphy; Kenneth M Murphy; Anne O'Garra
Journal:  Immunity       Date:  2009-07-30       Impact factor: 31.745

10.  CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis.

Authors:  Charles F Anderson; Mohammed Oukka; Vijay J Kuchroo; David Sacks
Journal:  J Exp Med       Date:  2007-02-05       Impact factor: 14.307

View more
  81 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Characterization of regulatory T cell (Treg) function in patients infected with Leishmania braziliensis.

Authors:  Diego L Costa; Luiz H Guimarães; Thiago M Cardoso; Adriano Queiroz; Ednaldo Lago; Ana M Roselino; Olívia Bacellar; Edgar M Carvalho; João S Silva
Journal:  Hum Immunol       Date:  2013-08-28       Impact factor: 2.850

3.  Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood.

Authors:  Om Prakash Singh; Kamlesh Gidwani; Rajiv Kumar; Susanne Nylén; Stephen L Jones; Marleen Boelaert; David Sacks; Shyam Sundar
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

4.  CD8 T cell exhaustion in human visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Neetu Singh; Abhishek Kumar Singh; Madhukar Rai; David Sacks; Shyam Sundar; Susanne Nylén
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

5.  A chemical inhibitor of heat shock protein 78 (HSP78) from Leishmania donovani represents a potential antileishmanial drug candidate.

Authors:  Sonali Das; Anindyajit Banerjee; Mohd Kamran; Sarfaraz Ahmad Ejazi; Mohammad Asad; Nahid Ali; Saikat Chakrabarti
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

6.  HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis.

Authors:  Bhawana Singh; Michaela Fakiola; Medhavi Sudarshan; Joyce Oommen; Siddharth Sankar Singh; Shyam Sundar; Jenefer M Blackwell
Journal:  Immunology       Date:  2018-11-22       Impact factor: 7.397

7.  Role of IL-21 in host pathogenesis in experimental visceral leishmaniasis.

Authors:  R Khatonier; A M Khan; P Sarmah; G U Ahmed
Journal:  J Parasit Dis       Date:  2018-08-22

8.  Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.

Authors:  Robert G Schaut; Tara L Grinnage-Pulley; Kevin J Esch; Angela J Toepp; Malcolm S Duthie; Randall F Howard; Steven G Reed; Christine A Petersen
Journal:  Vaccine       Date:  2016-09-21       Impact factor: 3.641

9.  Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.

Authors:  Henry W Murray; Yunhua Zhang; Yan Zhang; Vanitha S Raman; Steven G Reed; Xiaojing Ma
Journal:  Infect Immun       Date:  2013-04-15       Impact factor: 3.441

Review 10.  Interleukin-27: balancing protective and pathological immunity.

Authors:  Christopher A Hunter; Rob Kastelein
Journal:  Immunity       Date:  2012-12-14       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.